Quick Answer
Evofem Biosciences, Inc. reported Operating Income Loss of -$7.68 million for the year ending 2024.
- Evofem Biosciences, Inc. showed an increase of +57.0% in Operating Income Loss from 2023 to 2024.
- This data is from Evofem Biosciences, Inc.'s annual report (Form 10-K), filed with the SEC on March 24, 2025.
- XBRL data for this metric is available from 2013 to 2024 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2013 to 2024), Evofem Biosciences, Inc.'s Operating Income Loss has grown by 46.8%.
- Historical annual values: Fiscal year 2024: -$7.68 million | Fiscal year 2023: -$17.85 million | Fiscal year 2022: -$84.12 million | Fiscal year 2021: -$166.80 million | Fiscal year 2020: -$103.62 million | Fiscal year 2019: -$52.74 million | Fiscal year 2018: -$77.64 million | Fiscal year 2017: -$35.69 million | Fiscal year 2016: -$12.04 million | Fiscal year 2015: -$42.05 million | Fiscal year 2014: -$9.59 million | Fiscal year 2013: -$14.42 million.
- Data sourced from SEC EDGAR public filings as of June 20, 2026.
Last verified: